CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the National Medical Products Administration (NMPA) has granted approval for its lecanemab injection to enter clinical trials. This marks the first time a lecanemab biosimilar has received clinical‑trial clearance in China.
What Is Lecanemab?
- Monoclonal antibody that targets amyloid‑β (Aβ) plaques, continually clearing them and slowing Alzheimer’s disease progression.
- The original molecule, co‑developed by Eisai and Biogen, is marketed globally as LEQEMBI (approved in the U.S., Japan, EU, and China).
CSPC Pharma’s Biosimilar
- Developed with reference to LEQEMBI, the biosimilar was submitted under Category 3.3 of therapeutic biological products.
- Indication: Mild cognitive impairment due to Alzheimer’s disease and mild dementia associated with Alzheimer’s disease.
- Trial Status: NMPA approval enables the drug to proceed to phase I/II investigations in Chinese patients.
Strategic Implications
- Market Access: The approval positions CSPC Pharma as a pioneer in the Chinese biosimilar market for Alzheimer’s therapeutics, potentially capturing a share of the growing demand for disease‑modifying treatments.
- Competitive Edge: By offering a lower‑cost alternative to the branded LEQEMBI, CSPC may attract payers and clinicians seeking cost‑effective options without compromising efficacy.
- Regulatory Momentum: The NMPA’s willingness to fast‑track a complex biologic reflects a broader push to accelerate innovative therapies within China’s healthcare ecosystem.-Fineline Info & Tech
